Nalpain (Nalbuphine Hydrochloride)

Nalbuphine acts as a mixed opioid receptor agonist‑antagonist. It stimulates kappa receptors, producing analgesia, while blocking mu receptors, which reduces typical opioid side effects such as respiratory depression. This dual mechanism offers pain control with a ceiling effect on respiratory compromise.

The appropriate dose of Nalpain is determined by the prescribing clinician based on the patient’s pain severity, clinical condition, and route of administration. Dosage may vary for intramuscular, intravenous, or subcutaneous injection and should follow the prescriber’s specific instructions.

Safety of nalbuphine in pregnancy or lactation has not been fully established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Nalpain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with pure mu‑opioid agonists such as morphine, nalbuphine provides similar analgesia but with a lower risk of respiratory depression due to its mu‑antagonist activity. It also offers a ceiling effect for certain side effects, making it a useful alternative in patients where opioid‑induced respiratory compromise is a concern.

Nalpain should be stored below 25 °C in its original packaging. Protect the product from direct light and moisture to maintain stability. Do not freeze the solution, and keep it out of reach of children.

Nalpain is supplied as a sterile injectable solution and can be given by intramuscular, intravenous, or subcutaneous injection. The route, volume, and rate of administration are determined by the prescriber according to the clinical situation and patient needs.

The most serious risks include respiratory depression, severe hypotension, and rare allergic reactions such as anaphylaxis. Patients should be closely monitored for signs of breathing difficulty, sudden drop in blood pressure, or any hypersensitivity symptoms during and after administration.

Nalpain is contraindicated in patients with known hypersensitivity to nalbuphine or any component of the formulation, in those receiving monoamine oxidase inhibitors within 14 days, and in individuals with severe respiratory insufficiency where opioid‑induced depression could be life‑threatening.